Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,561
Total Claims
$1.5M
Drug Cost
653
Beneficiaries
$2,323
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+65%
Cost per patient vs peers
$2,323 vs $1,411 avg
+33%
Brand preference vs peers
14.1% vs 10.6% avg
Brand vs Generic
Brand: 1,752 claims · $1.1M
Generic: 10,661 claims · $368K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 266 | $242K |
| Icosapent Ethyl | 146 | $106K |
| Semaglutide | 66 | $78K |
| Sitagliptin Phosphate | 87 | $77K |
| Empagliflozin/Metformin Hcl | 97 | $65K |
| Sitagliptin Phos/Metformin Hcl | 85 | $63K |
| Apixaban | 72 | $63K |
| Icosapent Ethyl | 130 | $56K |
| Linaclotide | 88 | $48K |
| Rivaroxaban | 53 | $46K |
| Omega-3 Acid Ethyl Esters | 273 | $39K |
| Mirabegron | 62 | $36K |
| Insulin Glargine,hum.Rec.Anlog | 117 | $29K |
| Insulin Degludec | 76 | $28K |
| Tenofovir Alafenamide | 19 | $28K |
Prescribing Profile
Patient Profile
74
Avg Age
51%
Female
1.00
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data